Pectoral Nerve Blocks with Bupivacaine for Device Placement

Recruiting in Palo Alto (17 mi)

Overseen bySankalp Sehgal, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2 & 3

Waitlist Available

Sponsor: Beth Israel Deaconess Medical Center

Prior Safety Data

Trial Summary

What is the purpose of this trial?The purpose of this study is to determine whether administration of a pectoral nerve blocks (Pecs I and II) with 0.25% bupivacaine are more effective as compared to placebo to provide analgesia for cardiac implantable electronic device (CIED) placement in cardiac electrophysiology lab

Eligibility Criteria

This trial is for adults over 18 who are scheduled to receive a cardiac implantable electronic device (CIED) and will have anesthesia during the procedure. It's not for those in other studies, needing urgent procedures, using certain pain or psychiatric meds, with chronic opioid use, allergic to bupivacaine, or having unstable vital signs.

Inclusion Criteria

Undergoing CIED placement in electrophysiology lab

Patients 18 years of age or older

Booked with anesthesia service for the procedure

Exclusion Criteria

Current participation in another interventional study

Emergent procedures

You are using other types of regional anesthesia, such as intrathecal morphine.

+5 more

Participant Groups

The study tests if pectoral nerve blocks using 0.25% bupivacaine provide better pain relief than placebo during CIED placement in the heart electrophysiology lab. The goal is to see if this can reduce postoperative pain and improve patient satisfaction without opioids.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Bupivacaine GroupExperimental Treatment1 Intervention

Receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block

Group II: Control groupPlacebo Group1 Intervention

Receive up to 25 ml of normal 0.9% sodium chloride for the Pecs block